Literature DB >> 17123734

New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis.

Shan Sun1, Hong Cao, Mei Han, Ting-Ting Li, Hai-Li Pan, Zhi-Qi Zhao, Yu-Qiu Zhang.   

Abstract

Fractalkine, a chemokine binding to only one known receptor CX3CR1, has recently been proposed to be a neuron-to-glia signal in the spinal cord leading to microglial activation and glially dependent pain facilitation. The previous studies explored that blockade of endogenous fractalkine, using anti-CX3CR1 neutralizing antibody, dose-dependently attenuated neuropathic pain. The present study examined the role of endogenous fractalkine in inflammatory pain. Intra-articular injection of complete Freund's adjuvant (CFA)-induced rat ankle joint monoarthritis (MA) model was used. Western blot analysis revealed that CX3CR1 expression in the spinal cord was significantly increased following CFA-induced MA. Intrathecal injection of anti-CX3CR1 neutralizing antibody both delayed the development of mechanical allodynia and thermal hyperalgesia, and reversed established pain facilitation. Furthermore, blockade of CX3CR1 significantly suppressed activation of spinal glia, especially microglia, evoked by MA. These data provided new evidence for the contribution of endogenous fractalkine to the initiation and early maintenance of inflammatory pain facilitation via activating spinal microglia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123734     DOI: 10.1016/j.pain.2006.09.035

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  50 in total

1.  Spinal CX3CL1/CX3CR1 May Not Directly Participate in the Development of Morphine Tolerance in Rats.

Authors:  Yawen Peng; Genhua Guo; Bin Shu; Daiqiang Liu; Peng Su; Xuming Zhang; Feng Gao
Journal:  Neurochem Res       Date:  2017-08-03       Impact factor: 3.996

Review 2.  "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Erin D Milligan; Steven F Maier
Journal:  Brain Res Rev       Date:  2007-07-13

3.  Involvement of NF-κB and the CX3CR1 Signaling Network in Mechanical Allodynia Induced by Tetanic Sciatic Stimulation.

Authors:  Zhe-Chen Wang; Li-Hong Li; Chao Bian; Liu Yang; Ning Lv; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2017-06-13       Impact factor: 5.203

4.  Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.

Authors:  Hai-Li Pan; Ben-Long Liu; Wei Lin; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2016-09-09       Impact factor: 5.203

Review 5.  Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain.

Authors:  Gang Chen; Yu-Qiu Zhang; Yawar J Qadri; Charles N Serhan; Ru-Rong Ji
Journal:  Neuron       Date:  2018-12-19       Impact factor: 17.173

Review 6.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

7.  CX3CR1 Mediates Nicotine Withdrawal-Induced Hyperalgesia via Microglial P38 MAPK Signaling.

Authors:  Yonghong Ding; Wenhui Shi; Guannan Xie; Ailan Yu; Qinghe Wang; Zongwang Zhang
Journal:  Neurochem Res       Date:  2015-09-19       Impact factor: 3.996

8.  Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain.

Authors:  Wei Wang; Wen Wang; Xiaopeng Mei; Jing Huang; Yanyan Wei; Yayun Wang; Shengxi Wu; Yunqing Li
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

Review 9.  Chemokines as pain mediators and modulators.

Authors:  Fletcher A White; Natalie M Wilson
Journal:  Curr Opin Anaesthesiol       Date:  2008-10       Impact factor: 2.706

Review 10.  Neuron-glia crosstalk gets serious: role in pain hypersensitivity.

Authors:  Ke Ren; Ronald Dubner
Journal:  Curr Opin Anaesthesiol       Date:  2008-10       Impact factor: 2.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.